Chinese Biotech Sector Regains Mojo As Listings, Funding Deals Inject $357m
One initial public offering and six private funding deals add a total of $357m into the biotech funding pot in China as multiple new ventures look to progress pipeline assets and build capabilities.
You may also be interested in...
The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
Foreign medical device innovators accessing the Chinese market remain at a disadvantage to local companies, even after the recent regulatory pathway revision.